Summary Purpose: To determine the safety, in our practice, of allowing patient preference to influence the timing of antiepileptic drug (AED) reduction, once they became seizure-free after anterior temporal lobectomy (ATL). Methods: Thirty patients underwent anterior temporal lobectomy for medically intractable complex partial epilepsy at Loma Linda University Medical Center between December 1st 1991 and November 30th 2001. Timing of AED reduction in seizure-free patients was based on patient request. A review of patient records noted seizure status, duration from surgery to AED reduction, AED side effects, seizure recurrence and whether control was regained. Results: Twenty-four (80%) of the 30 patients became seizure-free on their preoperative AEDs after initial ATL; three additional patients after a second operation. AEDs were not reduced in the reoperated patients, the three patients who did not become seizure-free, and in two patients who asked to increase AEDs to control auras. Thus, AEDs were reduced in 22 of the 27 seizure-free patients. Patients were followed an average of 3.4 ± 2.7 (mean ± standard deviation) years. AED reduction was initiated 4.6 ± 7.2 months (range 0-27 months) after surgery. Polytherapy use decreased from 54% preoperatively to 18% at last follow up. Seizures recurred in six patients (27% of 22); three became seizure-free after AED adjustments. Conclusions: In our practice, using an individualized approach to AED reduction following successful epilepsy surgery resulted in early reduction in AEDs. Our data suggest that early AED reduction can be performed safely and without undue risk of seizure recurrence.
Introduction
Temporal lobe epilepsy affects 800,000 patients in the United States 1 with 100,000 of these estimated to be surgical candidates. 2 The annual rate for epilepsy surgery in the US is estimated to be 1500 patients. 3 Surgery results in better seizure control, a significant reduction in total number of antiepileptic drugs (AEDs) required, and in an increased number of patients off AEDs altogether. 4 Improvement is seen regardless of age, though with a trend towards better outcome with earlier intervention. 5 Complex partial epilepsy arising from a temporal lobe is the most common form of medically intractable epilepsy amenable to surgery--anterior temporal lobectomy (ATL). Worldwide, following ATL, a seizure-free status is achieved in approximately 68% of patients, and ''worthwhile'' improvement in another 24%. 6 A randomized, controlled trial in Canada recently confirmed a significant advantage of surgical over medical treatment for intractable temporal-lobe epilepsy, both in freedom from seizures and in quality of life. 3 The primary goal of surgery is a seizure-free status, which is the most important determinant of patients' quality of life after surgery. A secondary goal is reduction in number and dosage of AEDs, in order to reduce the burden of their side effects. A retrospective study in 93 patients reported a reduction in polytherapy (two or more AEDs taken by a patient) from 78% preoperatively to 47% at 6 months, 18% at 12 months, and 14% at 24 months. 7 A prospective, randomized study of 40 patients, comparing continuation of preoperative AEDs to conversion to carbamazepine monotherapy following surgery, showed no difference in seizure frequency during the first year. 2 A retrospective study of 210 consecutive patients in which AEDs were discontinued in 84 patients and reduced in 96 patients, showed emergence of seizures in 14% versus 3% at 2 years and 36% versus 7% at 5 years following surgery, showing an increased risk of recurrence in those who completely discontinued their AEDs. Risk of subsequent seizure was also increased in patients with a normal preoperative MRI scan. Interestingly, the seizure-free duration after surgery did not appear to impact the risk of subsequent seizures. 8 We had shown previously that recurrence of seizures within two months after surgery predicted a non-seizure-free status 2 years after surgery. 9 Thus, we had reason to expect that patients in whom seizures did not recur within two months of surgery would have a good prognosis for remaining seizure-free.
We report a retrospective review of the safety, in our practice, of allowing patient preference to influence the timing of AED reduction, once they became seizure-free after ATL.
Methods
Thirty patients underwent ATL for medically intractable complex partial epilepsy at Loma Linda University Medical Center (LLUMC) from December 1991 to November 2001.
The LLUMC Institutional Review Board approved a retrospective review of patient records and a mailed patient questionnaire. We collected descriptive data of the patients, their outcomes, and the timing and results of AED reduction in patients rendered seizure-free (Engel's Classification of Postoperative Outcome 10 Class 1A or 1B) by ATL.
A specific protocol for AED reduction or withdrawal was not followed. The timing of medication adjustments in seizure-free patients was influenced to varying extents by patient preference and continued until patients considered their condition optimally managed.
For the purpose of this review, patients were considered ''seizure-free'' if they did not experience complex partial or generalized tonic-clonic seizures while taking the medications as prescribed from the time of surgery until AED reduction was initiated or until the most recent clinic or mail follow-up.
Results
Twenty-four of the 30 patients became seizure-free on their preoperative AEDs after the first resection (80%). Three additional patients became seizure-free after a second surgery, for a total of 27 seizure-free patients (90%). AEDs were not reduced in the three patients who required additional surgery and in two other patients who asked to increase AEDs to control simple partial seizures. Consequently, AEDs were reduced in the remaining 22 patients (81% of the 27 seizure-free patients).
The entire group of 30 patients were followed an average of 3.4 ± 2.7 (mean ± S.D.) years. In the medication reduction group, follow up averaged 3.2 ± 2.7 (mean ± S.D.) years after surgery, with three (13%) followed less than 1 year, seven (32%) from 1 to 2 years, five (23%) for 2 to 5 years, and seven (32%) for more than 5 years. The three followed for less than 1 year were seizure-free with AED reductions at last available follow-up.
There were six patients who did not become seizure-free; three became seizure-free after a second operation. The postoperative seizures occurred within 2 months of surgery in four patients and within 12 months in two additional patients. Seizure recurrence from time of surgery averaged 3.8 ± 5.1 (mean ± S.D.) months. Table 1 compares Group 1, the seizure-free group of 22 who underwent AED reduction, with Group 2, which includes the three re-operated patients (now seizure-free), the two patients who requested AED increase to control their aura, and the three patients who never achieved a seizure-free state (continuing to have rare complex partial or generalized seizures). The characteristics of the two groups are similar except that the presurgical MRI results showed an abnormality in 17 (77%) of Group 1 compared to 4 (50%) of Group 2 (see Table 1 ).
The nature of the medication intolerance leading to AED reduction was as follows: cognitive effects in five cases, somnolence in two cases; fatigue, nausea, decreased libido, and depression one case of each. In three cases patients took the initiative to reduce their medication.
AED reduction was initiated in the 22 patients at a mean of 4.6 ± 7.2 (mean ± S.D.) months (range 0-27 months) after surgery. This occurred within 1 month of surgery in nine patients (41% of the 22 patients with AED reduction), in 1-2 months in four (18%), in 2-4 months in three (14%), in 4-6 months in two (10%), 6-12 months in two (10%), and 12-24 months in two (10%). As a result, polytherapy use dropped in these 22 patients from 12 (54%) preoperatively to 9 (41%) 2 months postoperatively, 4 (18%) at 6 months, 4 (18%) at 12 months, and at the last available follow-up. While not encouraged to do so, AEDs were discontinued after 24 months in two patients by their request. They remained seizure-free at follow-up, respectively, 2 and 8 months following discontinuation.
Seizures emerged in 6 (27%) of 22 patients seizure-free patients when AEDs were reduced. Seizures stopped in three patients after alternative AEDs were introduced or, less frequently, existing AEDs were increased (though not to their previous levels). Medication adjustment continues in the three other patients.
Discussion
Once patients became seizure-free, they were unwilling to tolerate the same burden of AED side effects that they had accepted when they were having uncontrolled seizures preoperatively. Our protocol of AED reduction initiated in response to our patients' requests lead to earlier reduction than the historical 1-2-year waiting period following surgery--the majority within 2-4 months. The majority (73%) underwent early AED reduction without seizure recurrence. Seizures recurred in 27%, and remained incompletely controlled in half (three patients or 14%). This finding concurs with the finding of Schiller et al. 8 that timing of AED reduction (or seizure-free duration) does not appear to be a risk factor for recurrence.
Looking back at our data, none of the demographic, clinical or surgical pathology data distinguished the subgroup who became seizure-free and in whom AEDs could be reduced from the remaining patients or the entire surgical group. This may be due to the small numbers, to patient selection, to our definition, applied retrospectively, of the seizure-free status for the purpose of initiating medication reduction, and to the weight we gave to patient preference regarding the timing of medication reduction.
Similarly, the 90% seizure-free number for our patient population cannot be compared to numbers in the literature because of the dynamic, time-dependent, way it is derived. The number includes three patients who required a second operation to become seizure-free, and, in those patients in whom AEDs were reduced, is based on an observation period extending only up to the time of initiation of medication reduction. If the three patients who required a second operation and the three patients who relapsed after medication reduction and have not been rendered seizure-free were classified as ''not seizure-free'', our numbers for the results of the first operation would be comparable to the general average.
Further, under-reporting of seizures by patients who undergo epilepsy is recognized, and was reflected recently in our own experience with one of two patients in the medication reduction group in whom seizures emerged.
Thus, inferences from these data should be constrained to the following: early, gradual, post-operative AED reduction in patients who become seizure-free after ATL may be accomplished with relative safety to the degree needed to ameliorate AED side effects.
Looking forward, application to our clinical practice includes: (1) an 8 in 10 success rate, (2) a willingness to reduce AEDs early after successful surgery (4 months on average) with a 1 in 4 risk of seizure recurrence, and (3) 1 in 2 likelihood of regaining a seizure-free state in those recur.
We currently view ATL as an important tool in the armamentarium to achieve a seizure-free status in selected patients with complex partial epilepsy, and do not subscribe to a predefined period of post-surgical observation before initiating medication changes. A particular advantage to patients of early AED adjustment is that it is easier to deal with the possibility of temporary emergence of seizures before patients begin or resume driving. Our data permit us to provide our patients with more precise estimates of the likelihood of the various postoperative and AED reduction outcomes. We introduce AED modifications early following surgery, taking into account the patients' perspectives, to achieve seizure-freedom with tolerable or no medication-related side effects.
